SILK-EYE SIGNED

Project "SILK-EYE" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Prevalent eye diseases, such as myopia, presbyopia, and corneal disease affect millions worldwide, but for now cannot be prevented. Surgical interventions of these conditions are turning to additive surgery, exemplified by corneal implants or the replacement of the natural crystalline lens by (or addition of) an intraocular lens, as it reduces complications of tissue removal surgeries.

Current eye treatments involving adding tissue or lenses exist in the form of amnion bandages, corneal inlays, and intraocular lenses. However, those approaches suffer from a number of shortcomings: corneal haze or rejection; risk of disease transmission, short lifespan, need of cryopreservation and donor tissue; lack of compliance of lens designs and biomaterials. In particular, no material has been found that fully meets the requirements for mechanical properties, transparency, biocompatibility and versatility for applications in the cornea and in accommodating intraocular lenses.

In recent years, silk fibroin derived from silkworm cocoons has emerged as a protein polymer for biomaterial applications. SILK-EYE will develop a new generation of corneal and intraocular implants, using silk-based materials tuned to each specific application and light enabling procedure. The silk-based implants will feature both the accessibility advantages of synthetic materials and the structural and biocompatibility properties of allografts, capitalizing on silk’s unique potential for transparency, controllable stiffness and degradability, refractive index and permeability, and their potential for light-induced cross-linking and bonding in the eye. SILK-EYE will design radically novel corneal dressings and implants, and accommodating intraocular lenses that are more biocompatible and functional than current synthetic implants, and are safer, more tunable, accessible and affordable than donor allografts, potentially revolutionizing how the major corrective procedures in ophthalmology are performed.